SARS-CoV-2 - COVID New in vitro data show the virus neutralising effect of Carragelose® on SARS-CoV-2

https://media.marinomed.com/df/cd/aa/morokutti-kurz-et-al-2021.pdf

About Carragelose(R,tm) <-> COVID
Carragelose(R) is a sulfated polymer derived from red algae with a unique broad spectrum virus-blocking activity. It is known as a tolerable, effective and safe agent for the prevention and treatment of respiratory viral diseases. Multiple clinical and preclinical studies have shown that Carragelose(R) forms a layer on the mucosa that surrounds and inactivates invading viruses, preventing them from infecting cells. Laboratory studies and clinical data have shown that Carragelose(R) can also inactivate SARS-CoV-2., Marinomed holds the patent rights to Carragelose(R) and has licensed Carragelose(R) for distribution in Europe, Canada, Australia and other countries in Asia and Latin America. Marinomed's Carragelose(R) portfolio of nasal sprays and products for the throat can be found at

https://www.carragelose.com/en/portfolio/launched-products

and the scientific publications on Carragelose(R) can be found at

https://www.marinomed.com/de/publikationen/wissenschaftliche-publikationen

Estim. target 127 € (135 USD) - Analysts at "Erste Group"
(that was before the P&G deal)

2002-05-04 - Analysts at "Erste Group" have lowered their price target for the shares of domestic Marinomed from 155.00 to 127.00 euros. The "buy" recommendation was confirmed by analyst Vladimira Urbankova.

Despite the company's lack of exposure to Russia/Ukraine markets and strong sales figures for 2021, Marinomed's share price has recently come under pressure, the latest report said. Taking into account recent news indicating delays in the launch of Budesolv on European markets, the revised price target is EUR 127.0, compared with the previous target of EUR 155.0, Erste experts added. However, an upside potential of more than 50 percent indicates that Marinomed's attractive investment story is far from being priced in, they added.

License agreement + Procter & Gamble <-> Marinomed

Marinomed, a listed biotechnology company based in Korneuburg, Lower Austria, has signed a licensing agreement with US consumer goods giant Procter & Gamble. As a result, the company's share price jumped sharply on the Vienna Stock Exchange on Friday morning.

The agreement covers the U.S. and certain Marinomed medical products that are protected by several patents, according to a company statement late Thursday night. Procter & Gamble is now taking the necessary steps to market those products in the United States, it said.

Marinomed is responsible for technology transfer, specifically providing P&G with the necessary data needed for regulatory approval. Under the terms of the agreement and depending on the achievement of certain regulatory and commercial milestones, Marinomed is entitled to receive so-called milestone payments as well as royalties on sales of the so-called Carragelose products for the treatment of diseases caused by respiratory virus infection.

The agreement covers the U.S. and certain Marinomed medical products that are protected by several patents. Procter & Gamble is now taking the necessary steps to market these products in the United States, he said.

While the announcement does not include financial details or information on the timing of a launch of Carrragelose products, it is nonetheless significant and has a positive impact on Marinomed's share valuation and price performance, Erste Group analyst Vladimira Urbankova says in an initial reaction. She writes of a "positive surprise for market participants" and refers to the current low price of the shares, which is at an inviting level - her "Buy" investment recommendation remains in place in view of this development.

Marinomed is responsible for technology transfer within the licensing agreement, according to the press release, specifically providing P&G with the necessary data needed for regulatory approval. Under the terms of the agreement, and depending on the achievement of certain regulatory and commercial milestones, Marinomed is eligible to receive so-called milestone payments as well as royalties on sales of the so-called Carragelose products for the treatment of diseases caused by respiratory virus infection.

___
helps also agains covid-19